ArticleMycopathologia2016
Nosocomial Bloodstream Infection Due to Candida spp. in China: Species Distribution, Clinical Features, and Outcomes.
Article in Mycopathologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Epidemiological characteristics, antifungal susceptibility, and mortality factors of candidemia in adults at a tertiary teaching hospital in Zunyi, China (2016-2023).BMC infectious diseases · 2025Article
- Identification of chicken-derived antibodies targeting the Candida albicans Als3 protein.Applied microbiology and biotechnology · 2025Article
- Clinical and molecular features of candidemia: a three-year retrospective study in Northern Guizhou, China.Frontiers in cellular and infection microbiology · 2025Article
- An AIE-active probe acts as novel tool for rapid and accurate quantitative antifungal susceptibility assessment.Frontiers in microbiology · 2025Article
- Antifungal activity of a maleimide derivative: disruption of cell membranes and interference with iron ion homoeostasis.Mycology · 2025Article
- Dual-antigen fusion protein vaccination induces protective immunity againstHuman vaccines & immunotherapeutics · 2024Article
- The role ofJournal of medical microbiology · 2024Article
- Comparison of microbial colonization rates between central venous catheters and peripherally inserted central catheters.Antimicrobial resistance and infection control · 2023Article
- Characterization of Virulence Factors inJournal of fungi (Basel, Switzerland) · 2023Article
- Lower risk of bloodstream infections for peripherally inserted central catheters compared to central venous catheters in critically ill patients.Antimicrobial resistance and infection control · 2022Article
- Systematic Characterization of Epidemiology, Antifungal Susceptibility, Risk Factors and Outcomes of Candidaemia: A Six-Year Chinese Study.Infection and drug resistance · 2022Article
- Intestinal Infection ofFrontiers in microbiology · 2021Review
- Molecular Epidemiology, Antifungal Susceptibility, and Virulence Evaluation ofFrontiers in cellular and infection microbiology · 2021Article
- Risk Factors ofFrontiers in public health · 2021Article
- A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China.Antimicrobial resistance and infection control · 2020Observational
- T-cell-specific mTOR deletion in mice ameliorated CD4Virulence · 2019Article
- Severe acute pancreatitis with blood infection by Candida glabrata complicated severe agranulocytosis: a case report.BMC infectious diseases · 2018Article
- Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.Mycopathologia · 2018Article
- Epidemiology of fungal infections in China.Frontiers of medicine · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the distribution of Candida spp., predictors of mortality, and effects of therapeutic measures on outcomes of nosocomial bloodstream infection (BSI) due to Candida spp.
methodsThis retrospective, population-based study enrolled adult patients with Candida nosocomial BSI from January 2010 to December 2014 in one tertiary care hospital. The demographics, comorbidities, species distribution, risk factors, and effects of antifungal treatment were assessed.
resultsIn total, 190 episodes of Candida BSI were identified. The most prevalent species was C. albicans (38.9 %), followed by C. parapsilosis (23.2 %) and C. tropicalis (20.5 %). In vitro susceptibility testing showed that 88.9 % of Candida isolates were susceptible to fluconazole. The 30-day hospital mortality was 27.9 %, while the early mortality (within 7 days) was 16.3 %. In a multivariate regression analysis, the Acute Physiology and Chronic Health Evaluation II score [odds ratio (OR) 1.23; 95 % confidence interval (CI) 1.080-1.390; P = 0.002] and severe sepsis or septic shock (OR 15.35; 95 % CI 2.391-98.502; P = 0.004) were independently correlated with early mortality. Severe sepsis or septic shock (OR 24.75; 95 % CI 5.099-120.162; P < 0.001) was an independent risk factor for 30-day mortality, while proven catheter-related candidemia (OR 0.16; 95 % CI 0.031-0.810; P = 0.027) was a positive factor for 30-day mortality. Early central venous catheter removal and adequate antifungal treatment were closely related to decreased mortality in patients with primary candidemia.
conclusionThe proportion of candidemia caused by C. albicans was lower than that caused by non-albicans species. The severity of illness influenced early mortality, and the origin of the central venous catheter remarkably affected 30-day mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.